Glaukos Corporation $GKOS Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its position in Glaukos Corporation (NYSE:GKOS – Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 651,456 shares of the medical instruments supplier’s stock after selling 10,219 shares during the period. William Blair Investment Management LLC owned approximately 1.10% of Glaukos worth $106,963,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Glaukos during the second quarter valued at approximately $1,333,318,000. Janus Henderson Group PLC grew its stake in shares of Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after buying an additional 2,329,608 shares during the last quarter. Jupiter Topco LLC purchased a new stake in shares of Glaukos in the second quarter worth approximately $679,614,000. Primecap Management Co. CA purchased a new stake in shares of Glaukos in the second quarter worth approximately $424,969,000. Finally, Bank of America Corp DE lifted its stake in shares of Glaukos by 22.0% during the 1st quarter. Bank of America Corp DE now owns 657,432 shares of the medical instruments supplier’s stock worth $70,779,000 after acquiring an additional 118,754 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Glaukos stock opened at $245.60 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. The stock has a market cap of $14.54 billion, a price-to-earnings ratio of -83.54 and a beta of 0.68. The firm has a 50-day moving average of $184.61 and a two-hundred day moving average of $147.10. Glaukos Corporation has a 1 year low of $87.32 and a 1 year high of $255.18.

Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The firm had revenue of $211.03 million during the quarter, compared to the consensus estimate of $168.04 million. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. The company’s revenue was up 58.0% on a year-over-year basis. On average, research analysts forecast that Glaukos Corporation will post 0.50 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Jefferies Financial Group boosted their price objective on Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, October 15th. HC Wainwright increased their target price on Glaukos from $195.00 to $248.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Needham & Company LLC lifted their target price on Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Finally, Wall Street Zen upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $218.00.

View Our Latest Analysis on Glaukos

Insider Transactions at Glaukos

In related news, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total value of $632,500.00. Following the transaction, the director owned 37,406 shares of the company’s stock, valued at $9,463,718. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.90% of the stock is currently owned by company insiders.

Glaukos Company Profile

(Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Further Reading

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.